Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

Table 2

Grade 3-4 toxicities per patient (total: 26).

	Number of patients (%)
Grade 3-4 haematologic toxicity
Neutropenia	2 (8)
Leucopenia	2 (8)
Thrombocytopenia	2 (8)
Grade 3-4 nonhaematologic toxicity
Venous thromboembolism	2 (8)
CNS hemorrhage*	1 (4)
Hepatic∧	1 (4)
Emesis	1 (4)

∗Asymptomatic central nervous system hemorrhage.
∧Transaminase increasing.